Table 3.
Outcomes between baseline and 12 months by subgroups of participants enrolled into the trial if they had central obesity and/or elevated HbA1c levels
| Baseline | Follow-up | Adjusted difference (95% CI) | P value | ||
| Inclusion based on central obesity | |||||
| Weight (kg) | Intervention | 83.1 (12.8) | 81.4 (13.0) | −1.1 (−1.7 to −0.5) | <0.0014 |
| Control | 81.8 (12.9) | 81.4 (13.6) | |||
| Waist circumference (cm) | Intervention | 106.6 (7.5) | 103.1 (9.1) | −1.8 (−2.4 to −1.3) | <0.001 |
| Control | 106.6 (7.7) | 105.1 (9.1) | |||
| SBP (mm Hg) | Intervention | 131.0 (16.6) | 130.6 (16.8) | −0.9 (−2.3 to 0.6) | 0.23 |
| Control | 132.4 (17.0) | 132.5 (17.1) | |||
| DBP (mm Hg) | Intervention | 81.3 (10.1) | 80.9 (10.1) | −0.6 (−1.5 to 0.3) | 0.19 |
| Control | 82.2 (10.4) | 82.4 (10.2) | |||
| HbA1c (%) | Intervention | 5.8 (0.4) | 5.8 (0.6) | −0.02 (−0.07 to 0.02) | 0.35 |
| Control | 5.7 (0.4) | 5.8 (0.5) | |||
| Inclusion based on HbA1c | |||||
| Weight (kg) | Intervention | 76.2 (14.5) | 74.5 (14.7) | −1.5 (−2.3 to −0.6) | <0.001 |
| Control | 75.4 (13.9) | 75.2 (14.5) | |||
| Waist circumference (cm) | Intervention | 100.4 (10.6) | 98.3 (11.1) | −2.1 (−3.0 to −1.2) | <0.001 |
| Control | 100.6 (11.1) | 100.5 (11.0) | |||
| SBP (mm Hg) | Intervention | 130.3 (17.5) | 132.4 (18.2) | −1.5 (−3.6 to 0.5) | 0.14 |
| Control | 131.4 (17.2) | 130.1 (17.2) | |||
| DBP (mm Hg) | Intervention | 80.5 (10.4) | 79.7 (10.5) | −1.6 (−2.8 to −0.4) | 0.009 |
| Control | 80.6 (10.4) | 81.6 (10.9) | |||
| HbA1c (%) | Intervention | 6.2 (0.1) | 6.2 (0.7) | −0.01 (−0.08 to 0.06) | 0.69 |
| Control | 6.2 (0.1) | 6.2 (0.5) | |||
Data are presented as mean and SD. Adjusted group differences are adjusted for stratification variables at randomisation (country and site), confounders (sex and age) and for corresponding baseline value.
DBP, diastolic blood pressure; HbA1c, haemoglobin A1c; SBP, systolic blood pressure.